Net Loss Per Share

3 Months Ended

Mar. 31, 2022

13. Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per Class A common share attributable to Rani Holdings (in thousands, except per share data):


	Three Months Ended March 31,
	2022
Numerator:
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.	$	(6,223	)
Denominator:
Weighted average Class A common share outstanding—basic and diluted		21,409
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.—basic and diluted	$	(0.29	)

The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per Class A common share attributable to Rani Holdings:


	Three Months Ended March 31,
	2022
Paired Interests		24,773,286
Stock options		3,375,756
Class A Units of Rani LLC exchangeable for Class A common stock		1,387,471
Restricted stock units		996,500
Restricted stock awards		96,363
		30,629,376

Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. The outstanding shares of Class B common stock were determined to be anti-dilutive for the three months ended March 31, 2022. Therefore, they are not included in the computation of net loss per Class A common share attributable to Rani Holdings.